Comparison between α-synuclein wild-type and A53T mutation in a progressive Parkinson's disease model

Biochemical and Biophysical Research Communications

Volumn 464, Issue 4, 2015, Pages 988-993

  Lu, Jianqing ^a   Sun, Feiyi ^a   Ma, Hong ^a   Qing, Hong ^a   Deng, Yulin ^a  

^a BEIJING INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Animal model; Parkinson's disease; Recombinant adeno associated virus; synuclein

Indexed keywords

ALPHA SYNUCLEIN; PARVOVIRUS VECTOR; APOMORPHINE; MUTANT PROTEIN; RECOMBINANT PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN NERVE CELL; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; GENE EXPRESSION; GENE MUTATION; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SUBSTANTIA NIGRA PARS COMPACTA; VIRUS RECOMBINANT; WILD TYPE; AGE; AMINO ACID SUBSTITUTION; ANIMAL; BRAIN; DISEASE MODEL; GENETICS; METABOLISM; MISSENSE MUTATION; PARKINSONIAN DISORDERS; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PROTEINOSIS; TORSION ABNORMALITY; TRANSGENIC RAT; WISTAR RAT;

ADENO-ASSOCIATED VIRUS; ANIMALIA; RATTUS;

AGE FACTORS; ALPHA-SYNUCLEIN; AMINO ACID SUBSTITUTION; ANIMALS; APOMORPHINE; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; IMMUNOHISTOCHEMISTRY; MALE; MUTANT PROTEINS; MUTATION, MISSENSE; PARKINSONIAN DISORDERS; PHOSPHORYLATION; PROTEIN AGGREGATION, PATHOLOGICAL; RATS; RATS, TRANSGENIC; RATS, WISTAR; RECOMBINANT PROTEINS; TORSION ABNORMALITY;

EID: 84940459255     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.07.007     Document Type: Article

References (19)

1. T.R. Mhyre, J.T. Boyd, R.W. Hamill, and K.A. Maguire-Zeiss Parkinson's disease Subcell. Biochem. 65 2012 389 455
2. R. Abdullah, I. Basak, K.S. Patil, G. Alves, J.P. Larsen, and S.G. Moller Parkinson's disease and age: the obvious but largely unexplored link Exp. Gerontol. 68 2015 33 38
3. J. Bove, and C. Perier Neurotoxin-based models of Parkinson's disease Neuroscience 211 2012 51 76
4. K.E. Paleologou, and O.M. El-Agnaf Alpha-synuclein aggregation and modulating factors Subcell. Biochem. 65 2012 109 164
5. J. Blesa, and S. Przedborski Parkinson's disease: animal models and dopaminergic cell vulnerability Front. Neuroanat. 8 2014 155
6. O.-W. Merten, and M. Al-Rubeai Viral Vectors for Gene Therapy: Methods and Protocols 2011 Humana Press New York
7. J.B. Koprich, T.H. Johnston, P. Huot, M.G. Reyes, M. Espinosa, and J.M. Brotchie Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein PLoS One 6 2011 e17698
8. A. Ulusoy, M. Decressac, D. Kirik, and A. Björklund Chapter 5-viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease B. Anders, M.A. Cenci, Progress in Brain Research 2010 Elsevier 89 111
9. M. Decressac, B. Mattsson, and A. Bjorklund Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease Exp. Neurol. 235 2012 306 315
10. A. Van der Perren, C. Van den Haute, and V. Baekelandt Viral vector-based models of Parkinson's disease Curr. Top. Behav. Neurosci. 22 2015 271 301
11. G. Taschenberger, M. Garrido, Y. Tereshchenko, M. Bahr, M. Zweckstetter, and S. Kugler Aggregation of alphaSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons Acta Neuropathol. 123 2012 671 683
12. V. Bonifati Genetics of Parkinson's disease-state of the art, 2013 Parkinsonism. Relat. Disord. 20 Suppl. 1 2014 S23 S28
13. P.O. Fernagut, and M.F. Chesselet Alpha-synuclein and transgenic mouse models Neurobiol. Dis. 17 2004 123 130
14. E. Masliah, E. Rockenstein, I. Veinbergs, M. Mallory, M. Hashimoto, A. Takeda, Y. Sagara, A. Sisk, and L. Mucke Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders Science 287 2000 1265 1269
15. L.J. Martin, Y. Pan, A.C. Price, W. Sterling, N.G. Copeland, N.A. Jenkins, D.L. Price, and M.K. Lee Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death J. Neurosci. 26 2006 41 50
16. D. Kirik, C. Rosenblad, C. Burger, C. Lundberg, T.E. Johansen, N. Muzyczka, R.J. Mandel, and A. Bjorklund Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system J. Neurosci. 22 2002 2780 2791
17. M. Oliveras-Salva, A. Van der Perren, N. Casadei, S. Stroobants, S. Nuber, R. D'Hooge, C. Van den Haute, and V. Baekelandt rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration Mol. Neurodegener. 8 2013 44
18. M. Decressac, B. Mattsson, M. Lundblad, P. Weikop, and A. Bjorklund Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons Neurobiol. Dis. 45 2012 939 953
19. J.B. Koprich, T.H. Johnston, M.G. Reyes, X. Sun, and J.M. Brotchie Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease Mol. Neurodegener. 5 2010 43